Cellectar Biosciences宣布欧洲药品管理局确认其符合条件,可为Iopofosine I 131申请有条件上市许可,用于治疗难治性(BTK抑制剂治疗后)华氏巨球蛋白血症

美股速递
Oct 06

Cellectar Biosciences宣布,欧洲药品管理局已确认该公司符合条件,可为其药物Iopofosine I 131申请有条件上市许可,该药物用于治疗难治性(BTK抑制剂治疗后)华氏巨球蛋白血症。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10